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BACKGROUND: Bone marrow transplantation with mi-
nor ABO incompatibility may be followed by moderate
delayed hemolysis of the recipient’s red cells by donor-
derived ABO antibodies. This reaction may be more se-
vere after transplantation of peripheral blood progenitor
cells (PBPCs).
CASE REPORT: A 16-year-old boy underwent an allo-
geneic PBPC transplant from his HLA-mismatched
mother as treatment for acute myeloblastic leukemia
that had proved resistant to induction chemotherapy.
Transfusion of the unmanipulated PBPCs proceeded
without any complication, despite the difference in ABO
blood group (donor, O Rh-positive; recipient, A Rh-posi-
tive). On Day 7, a rapid drop in hemoglobin to 4 g per dL
was observed, which was attributed to a massive
hemolysis. All the recipient’s group A red cells were de-
stroyed within 36 hours. This delayed and rapidly pro-
gressive hemolytic anemia was not associated with the
transfusion of the donor’s plasma. Rather, the anti-A titer
increased in parallel with marrow recovery, which sug-
gested an active synthesis of these antibodies by immu-
nocompetent cells from the donor against the recipient’s
red cells. The mother’s anti-A titer was retrospectively
found to be 2048. Her unusually high titer is probably
due to prior sensitization during pregnancies. On Day
12, the patient developed grade IV graft-versus-host dis-
ease, which proved resistant to all treatments instituted
and led to his death on Day 35.
CONCLUSION: PBPC transplantation with minor ABO
incompatibility may be associated with significant risk of
massive delayed hemolysis.
Bone marrow transplantation can be carried outsuccessfully between donors and recipients whohave ABO incompatibilities, provided that mea-sures are taken to avoid acute hemolytic reac-
tions after the transfusion of incompatible red cells (RBCs).1,2
There are two types of ABO incompatibility. One type, re-
ferred to as minor, may involve hemolysis after the destruc-
tion of a proportion of the patient’s RBCs by the anti-A or
anti-B present in the small quantity of plasma contained in
the graft. The other type, referred to as major, involves the
systemic presence in the recipient of ABO antibodies
against the RBC antigens of the donor. These antibodies will
mediate severe acute hemolytic reactions if the incompat-
ible RBCs are not removed from the graft.
We present a case of massive delayed hemolysis of the
recipient’s RBCs by donor-derived ABO antibodies after
peripheral blood progenitor cell (PBPC) transplant with
minor ABO incompatibility. This hemolysis was probably
due to recall immunity in relation to previous pregnancies
of the donor, in the context of an extremely precocious re-
covery of donor-derived white cells, which is a result of the
very rapid hematopoietic engraftment associated with
PBPCs and the use of granulocyte–colony-stimulating fac-
tor (G–CSF).
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CASE REPORT
A 16-year-old boy was diagnosed with acute myeloblastic
leukemia M1 according to the FAB classification, with tri-
somy 8, in the context of back pain as well as multiple fe-
brile episodes that were resistant to antibiotics. He had no
other particular antecedent medical problem. He under-
went a first course of induction chemotherapy with
mitoxantrone, arabinoside-cytosine (ara-C), and etoposide,
which resulted in failure, with persistence of 16-percent
blast cells in the bone marrow. A second line of treatment
based on amsacrine and intermediate-dose ara-C was then
administered, but the patient again did not reach a com-
plete remission. In light of this refractory leukemia, an al-
logeneic transplant was proposed as the therapeutic solu-
tion of last resort, in full awareness that it represented only
a 10-percent chance of cure. The preparative regimen con-
sisted of ara-C, cyclophosphamide, and an 8-Gy single dose
of total body irradiation, with intrathecal administration of
methotrexate. Infection prophylaxis was based on
trimethoprim/cotrimoxazole, ciprofloxacin, fluconazole,
and ganciclovir before transplant, followed by acyclovir af-
ter transplant, as well as polyvalent immunoglobulins.
Graft-versus-host disease (GVHD) prophylaxis consisted of
cyclosporine A alone.
The donor was the patient’s mother, who had a major
HLA mismatch at the D locus, as well as a different ABO
group (donor, O Rh-positive; recipient, A Rh-positive). It
should be noted that she had undergone four pregnancies
and had received one RBC transfusion. To carry out the
transplant, the donor’s marrow was stimulated with G–CSF
(10 µg/kg) for 5 days and PBPCs were collected by
cytapheresis on 2 consecutive days. Erythropoietin, 600 U
per kg twice a week, was also given for 3 weeks before and
3 weeks after the transplant, to proceed in parallel with the
collection of autologous RBC concentrates for use in the
recipient as needed. The return of the unmanipulated
PBPCs (12.23 × 106 CD34+ cells/kg) proceeded without
complication, and, in particular, no acute hemolytic reac-
tion was engendered on Day 0 or Day 1. From that time on,
the patient received only filtered and irradiated O Rh-posi-
tive RBC concentrates (these being by priority those taken
from the donor), as well as group O Rh-positive single-do-
nor platelet concentrates resuspended in group A plasma.
The patient was provided with 5 µg per kg of G–CSF
from Day 1 through Day 12 and with 200 U per kg of eryth-
ropoietin from Day 1 through Day 33. Neutrophil recovery
was prompt, with 0.5 × 109 polymorphonuclear neutrophils
per L achieved on Day 9 and 2 × 109 on Day 10. The plate-
lets never attained a value of 20 × 109 per L, as their recov-
ery was hampered by the severe gastrointestinal bleeding
observed later. As for the RBC lineage, early signs of recov-
ery were noted by Day 10, with a reticulocyte count of 1
percent, which attained a maximum value of 14 percent on
Day 20 before returning to aplastic values thereafter. How-
ever, the patient never became independent of transfusion,
first because of hemolysis and then because of the gas-
trointestinal bleeding (see below).
The posttransplant course was first complicated by
Staphylococcus epidermidis bacteremia on Day 3. Then, the
hemoglobin dropped dramatically from 8.5 g per dL on Day
6 to 4 g per dL on Day 8, without any evidence of bleeding
(Fig. 1). The drop in hemoglobin occurred concomitantly
with hematopoietic recovery, which was also accompanied
by a major increase in serum bilirubin (556 µmol/L on Day
8) and lactate dehydrogenase (1218 IU/L on Day 9), a com-
plete disappearance of haptoglobin, and a positive direct
antiglobulin test. Renal function was maintained. The
group A RBCs from the recipient were accordingly de-
stroyed within 36 hours. The recipient was group A until Day
6, showed a mixed-field population with very few group A
RBCs among group O cells on Day 7, and was group O from
Day 8 on (Table 1). The anti-A titer in the recipient was 0
through Day 6, 4 on Day 7, and 128 on Day 8. Consequently,
there was no agglutination of group A RBCs in the presence
of the patient’s serum until after Day 6, when there was
weak agglutination on Day 7 and 2+ agglutination from Day
8 on. The patient was treated with RBC transfusions, corti-
costeroids, and four sessions of plasmapheresis. This al-
lowed the hemolysis to resolve rapidly after all the patient’s
group A RBCs had been destroyed.
In the same period (i.e., Day 6-12), the patient devel-
oped acute GVHD, which attained an overall maximum
grade of IV on Day 12, including grade III skin GVHD, grade
IV hepatic GVHD, and grade IV gastrointestinal GVHD, the
latter of which was responsible for massive uncontrollable
bleeding that compromised survival.  Aggressive therapy in-
-- -- Lactate dehydrogenase (IU/L) (Scale 1)
— — Bilirubin (µmol/L) (Scale 1)
— — Hemoglonbin (g/dL) (Scale 2)
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Fig. 1. Evolution of hematologic and hemolytic measures in
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cluding cyclosporine A, corticosteroids, M24 monoclonal
antibodies, methotrexate, and anti-thymocyte globulin
proved unable to improve GVHD. On Day 24, a pulmonary
infection of undetermined origin developed, causing the
general condition to deteriorate further. Death followed on
Day 35, caused by liver failure and massive gastrointestinal
bleeding secondary to acute GVHD.
DISCUSSION
The presence in the recipient of ABO antibodies against the
RBC antigens of the donor is referred to as major ABO in-
compatibility. (This was not the case in our patient.) Apart
from the risk of acute hemolysis at the time of transplant,
there is also the fear that, if progenitor cells express ABO
antigens, there could be an additional risk of graft rejection.
However, this type of incompatibility does not engender
GVHD or prejudice the prognosis for survival.1,2 In fact,
rather than rejection of the graft, it seems to cause a pro-
longed RBC aplasia. To prevent complications, it is neces-
sary to process the bone marrow ex vivo to eliminate the
RBCs from the graft and in rare cases to carry out
pretransplant plasma exchanges in the recipient.1-4 In most
recipients, the antibodies disappear within 2 to 3 months,
but, in those who present with high levels before transplant,
there may be a rapid delayed increase in their titer with
consecutive RBC aplasia.
Minor ABO incompatibility can be defined by the pres-
ence in the donor of ABO antibodies directed against the
recipient’s RBCs, as observed in our patient. This occurs in
approximately 30 percent of marrow transplants and may
be somewhat more frequent in the unrelated-donor set-
ting.5 This situation is of concern only when the plasma
antibody titer of the donor is such that it is likely to induce
in the patient a hemolytic reaction during the return of the
marrow, [which in the latter case the plasma] should be re-
moved.2 Allogeneic bone marrow transplantation carried
out under these conditions can in general be performed
without any acute problem. In principle, there is no effect
on marrow recovery, no apparent increase in GVHD, and no
consequence for the survival of the recipient. However, it
appears that a moderate, delayed hemolytic reaction may
occur 9 to 16 days after bone marrow transplantation in 10
to 30 percent of the cases.5,6 Rarely, massive hemolysis has
been reported.7 Theoretically, a PBPC graft could further
increase this hemolytic risk, with regard to its lymphocyte-
enriched content,8 but there are no epidemiologic data
available to support this.
The patient discussed here never received plasma,
with the exception of a small volume at the time of the
transplant, which did not produce any significant degree of
hemolysis. The serum from the donor, in this case the
mother, did not contain any HLA antibodies but did have a
substantial anti-A titer (2048), probably induced by her
multiple previous pregnancies. An anamnestic immune
response may have favored the high titer of A antibodies in
the recipient, actively produced by the lymphocytes grafted
from the donor. These events were associated with a very
precocious marrow recovery and caused a massive destruc-
tion of the recipient’s RBCs.
Our case is the sixth reported in the literature of
hemolysis after allogeneic minor-incompatible PBPC trans-
plantation.8-12 Most cases occurred in the context of the
transplant of group A PBPCs to group O recipients (Table
2). Although it theoretically could further increase the risk
of hemolysis, a high antibody titer in the donor does not ap-
pear to be required for this to happen. This episode, com-
bined with very severe acute GVHD, precipitated the deg-
radation of the general condition of the patient, leading to
death. Whereas no HLA antibodies were detected in the
mother, the patient developed very severe GVHD immedi-
ately after hematologic recovery, despite the classic use of
cyclosporine A. Cyclosporine A is capable of stimulating an
exaggerated immune response that favors the proliferation
of B-lymphocytes, combined with the suppression of the
helper T-lymphocytes, which allows for the development of
hemolysis.5,6
Because of the very high risk of leukemia relapse in this
patient, no intravenous methotrexate was given, in the
hope of inducing a graft-versus-leukemia effect. The fact
that no methotrexate had been received may likewise have
contributed to the development of the hemolytic reaction,
inasmuch as this medication is toxic to B-lymphocytes and
may therefore prevent the production of the antibodies
necessary for the occurrence of the passenger lymphocyte
syndrome.5,8 Indeed, among PBPC cases, only one patient
received 2 doses of methotrexate (Table 2), and GVHD pro-
phylaxis incorporating methotrexate prevented the syn-
drome after marrow transplantation.5 The literature like-
wise makes reference to the fact that methotrexate may
prevent hemolysis affecting transfused group O RBCs that
is possibly mediated through absorption of A or B antigens
on their surface.5 High doses of intravenous immunoglobu-
lins may also be associated with a brief episode of moder-
TABLE 1. Immunohematologic findings in the patient
Patient’s serum ABO
Day and A1 RBCs Anti-A titer phenotype
0 Negative Negative A
1 Negative Negative A
2 Negative Negative A
4 Negative Negative A
6 Negative Negative A
7 (+)* 4 †
8 ++‡ 128 O
* Weakly positive.
† Mixed-field population with very few group A RBCs in group O
RBCs.
‡ 2+ agglutination.
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ate hemolysis immediately after their infusion.5 All these
factors may have contributed to the massive hemolysis that
developed in our patient.
Our observation confirms the potential hemolytic risk
of using a graft of PBPCs with a minor ABO incompatibil-
ity.8-12 Two additional considerations may have accentuated
the phenomenon in our patient: 1) a gestational sensitiza-
tion and 2) a high lymphocyte content in the graft. This type
of hemolytic reaction could be minimized by the inclusion
of methotrexate in the program of GVHD prophylaxis,
as well as by the elimination of  B-lymphocytes from the
graft—for instance, through CD34 selection.
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TABLE 2. Clinical and laboratory data on patients with immune hemolysis after allogeneic minor ABO-incompatible
PBPC transplantation*
Toren Laurencet Oziel Moog Bornhaüser
Our patient et al.8 et al.9 et al.10 et al.11 et al.12
Disease AML ALL MM MM AML CML
Age 16 12 37 38 19 23
Conditioning araC + Cy + TBI ? Cy + TBI Cy + TBI ? BU + Cy
Donor/recipient blood group O/A O/A O/A O/A ?/? B/A
Anti-A titer in donor 2048 32 64 8 ? 4
GVHD prevention CyA CyA CyA + mPDN CyA + mPDN CyA CyA (+MTX)
GVHD grade IV ? II 0 ? IV
CD34+ cells/transplanted/kg 12.2 × 106 ? 5 × 106 3.5 × 106 10 × 106 6 × 106
Time to 500 PMNs/µL Day 5 ? ? Day 8 ? Day 9
Day of hemolysis Day 7 Day 8 Day 10 Day 9 Day 6 Day 5
Peak bilirubin (mg/L) 325 614 62 390 40-45 180
Peak LDH (IU/L) 1218 6800 1464 3600 450-500 1040
Death (cause) Day 35 Alive (?) Alive Day 20 Alive Day 58
(GVHD) (MOF) (hemorrhage)
* AML = acute myeloblastic leukemia; MM = multiple myeloma; ALL = acute lymphoblastic leukemia; CML = chronic myelogenous leukemia ;
Cy = cyclophosphamide; Bu = busulfan; TBI = total body irradiation; MTX = methotrexate; mPDN = methylprednisolone; MOF = multi-organ
failure; PMNs = polymorphonuclear neutrophils ; LDH = lactate dehydrogenase.
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